ENGN

Business Context and Reporting Period

Company: enGene Holdings Inc. (ENGN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 31, 2025
Business Overview: enGene is a clinical-stage biotechnology company developing non-viral genetic medicines, primarily focused on its lead candidate, detalimogene voraplasmid (detalimogene), for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company operates as a single segment and has not yet generated any revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $13.19 million (79%) for the three months ended July 31, 2025, compared to the same period in 2024. This was driven by a $11.03 million increase in Research and Development (R&D) and a $2.16 million increase in General and Administrative (G&A) expenses.
• R&D Spend: R&D expenses rose significantly due to increased manufacturing and clinical activities for the LEGEND study of detalimogene and the hiring of key personnel to support clinical operations and quality functions.
• Net Loss: Net loss for the nine months ended July 31, 2025, was $79.42 million, compared to $39.84 million in the prior year period, reflecting the accelerated burn rate associated with clinical trial progression.
• Cash Position: Cash and cash equivalents decreased from $173.00 million at October 31, 2024, to $32.62 million at July 31, 2025. However, total liquidity (including marketable securities) remains at approximately $224.9 million.
• Debt Structure: The company has a term loan facility with Hercules Capital. As of July 31, 2025, $22.5 million has been drawn, with $27.5 million remaining available subject to conditions. The current portion of the note payable increased to $5.41 million.

Guidance, Outlook, and Risks

• Clinical Outlook: The company is advancing the Phase 2 LEGEND study for detalimogene. Management plans to file a Biologics License Application (BLA) with the FDA in the second half of 2026, contingent on positive data from the pivotal cohort.
• Liquidity Outlook: Management believes existing cash, cash equivalents, and marketable securities ($224.9 million) are sufficient to fund operations and debt obligations for at least the next 12 months from the issuance date of the report.
• Capital Needs: The company expects to incur significant expenses and operating losses for the foreseeable future. Substantial additional funding will be required to support commercialization efforts if approval is obtained. Future funding may come from equity offerings, debt financings, or collaborations.
• Internal Controls: The company disclosed that three material weaknesses in internal control over financial reporting remain unremediated as of July 31, 2025. These include deficiencies in formal policies, IT general controls, and segregation of duties. Consequently, disclosure controls and procedures were deemed ineffective.
• Risk Factors: Key risks include the heavy dependence on the success of detalimogene, the uncertainty of clinical trial outcomes, the need for additional capital, and the potential inability to raise funds on favorable terms.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $224.9 million liquidity position against the accelerating burn rate (approx. $29M quarterly loss) to confirm the 12-month runway assertion.
• Clinical Milestones: Monitor enrollment and interim efficacy data for the LEGEND Phase 2 pivotal cohort, which is critical for the planned H2 2026 BLA filing.
• Debt Covenants: Review the terms of the Hercules Capital term loan, specifically the conditions required to draw the remaining $27.5 million tranche and the impact of the 11.63% effective interest rate.
• Internal Controls: Assess the progress of remediation efforts regarding the three unremediated material weaknesses in internal controls over financial reporting.
• Dilution Risk: Evaluate the potential dilution from outstanding warrants (8.5 million) and stock options (9.4 million), as well as the $100 million Open Market Sale Agreement with Jefferies LLC.